NL0015285941 - Common Stock
IMMATICS NV
NASDAQ:IMTX (4/25/2024, 7:00:02 PM)
After market: 9.78 0 (0%)9.78
-0.37 (-3.65%)
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 210 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
IMMATICS NV
Paul Ehrlich-Strasse 15
Tuebingen BADEN-WUERTTEMBERG 72076
P: 4970715397700
CEO: Harpreet Singh
Employees: 210
Website: https://immatics.com/
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immatics (NASDAQ:IMTX) just reported results for the fourth quarter of 2023.Imm...
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median...
Here you can normally see the latest stock twits on IMTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: